Bextra, a Pfizer pain drug that received a sales boost when Mercks Vioxx was pulled from the market, will probably be tagged with the most prominent type of safety warning used by the Food and Drug Administration. 

According to Pfizer (nyse: PFE news people ), Bextra can cause a rare but sometimes life-threatening drug reaction called Stevens-Johnson Syndrome in which the skin, mouth, and eyes can become horribly blistered. Other drugs, including Pfizers arthritis pill Celebrex, can also cause this condition but it seems to be more common with Bextra than other medications. Patients taking Bextra who develop the condition tend to get it in the first two weeks of treatment.

Bextra causes Stevens-Johnson Syndrome more often than Celebrex, a similar Pfizer pain drug, and Pfizer has been in discussions with the Food and Drug Administration about how to include the risk in the drugs label. In its third quarter regulatory filing, the drug giant said these discussions would likely to lead to a black box warning in which warning language is displayed in bold type on a drugs packaging. Pfizer had already communicated the risk to doctors in an Oct. 15 letter.

Timothy Anderson, an analyst at Prudential Equity Group, first reported the likely labeling change in a note to investors Friday night. Anderson noted that many drugs have warnings in their labels about the risk of Stevens-Johnson Syndrome, but few contain a black box. A black-box warning on Bextra will impair [Pfizers] ability to market the drug, Anderson wrote, which suggests the commercial future of Bextra is at risk.

Previously, Anderson had estimated 2005 Bextra sales of $1.7 billion, up from $990 million in 2003. He now believes that number may need to be scaled back. Bextra is in the same class of medicines as Vioxx, the Merck (nyse: MRK news people ) pill that was pulled from the market because it doubled the risk of heart attack and stroke.

Bextra has also been linked heart risk in high-risk patients. Pfizer revealed last month that the drug increased the risk of heart attack in patients who had undergone open-heart surgery in two separate studies. Those results were also included in the October 15 letter to doctors.

The risk did not turn up in other studies of the drug in surgery, and Bextra has not been approved for post-surgical use. Still, Pfizer has also been discussing the open-heart surgery data with the FDA, says Pfizer spokeswoman Susan Bro, and that data is also likely to be reflected in the products label. She said that Bextra is still an important option for patients, but said that both side effects, though rare, are serious.

The Vioxx withdrawal has resulted in increased scrutiny for Celebrex and Bextra, which inhibit inflammation in the same way. Prexige, another similar drug being developed by Novart is (nyse: NVS news people ), has been delayed for at least a year.

In defending Celebrex, Pfizer points to extensive data and the millions of patients who have taken the drug. In a bold move, Pfizer is testing Celebrex in patients at high risk for heart attacks and it says it expects the drug may actually reduce cardiovascular disease.



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Bextra, Celebrex MDL judge sets first Bextra trial

On the heels of the $4.85 Billion Vioxx settlement, the Multi-District Litigation (MDL) Court for the...

Bextra

What is Bextra? Bextra is valdecoxib-based drug that is administered orally. Bextra is used as...

Health Canada Prohibits Sale Of Bextra In Canada

Following a review of safety information, Health Canada is informing the public that Bextra, an...

Bextra's Return Barred by Health Canada

Bextra is a member of a class of drugs known as cox-2 inhibitors. Better known cox-2s are Celebrex,...

FDA Rejects Bextra-Like Drug

The FDA has decided not to approve a special formulation of Pfizer's recalled pain reliever Bextra that...

U.S. asks Pfizer for Celebrex, Bextra Documents

The U.S. Securities and Exchange Commission has asked Pfizer Inc. for information about two of its...

Respectful, understanding, efficient and compassionate

Beasley Allen is one of the most professional organizations I have ever had the pleasure of working with. They are respectful, understanding, efficient, and above all compassionate. They take the best care of their clients in every way possible. They keep us informed and aware of things involved in their clients cases. Their counsel is stellar in the industry. I would highly recommend them to others in their time of need and I have done so.

—Chad